Tech Company Financing Transactions
NextCure Funding Round
On 1/7/2016, NextCure secured $67 million in Series A investment from Alexandria Venture Investments, Canaan Partners and Lilly Asia Ventures.
Transaction Overview
Company Name
Announced On
1/7/2016
Transaction Type
Venture Equity
Amount
$67,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
9000 Virginia Manor Rd. 200
New Haven, CT 20705
USA
New Haven, CT 20705
USA
Phone
Website
Email Address
Overview
NextCure (Nasdaq: NXTC), launched in 2015, is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Richman
Chief Financial Officer
Steven Cobourn
Vice President
Linda Liu
VP - Bus. Development
James Bingham
VP - Bus. Development
Sebastien Maloveste
VP - Bus. Development
Timothy Mayer
VP - Regulatory Affairs
Sol Langermann
Browse more venture capital transactions:
Prev: 1/7/2016: Entac Medical venture capital transaction
Next: 1/7/2016: Scalr venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC transactions reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs